Electrocardiographic Aging in Genetic Cardiomyopathies: Insights from an Artificial Intelligence-Enabled Electrocardiogram Analysis
Abstract Body (Do not enter title and authors here): Background: Arrhythmogenic and dilated cardiomyopathies (ACM/DCM) are associated with adverse cardiovascular outcomes, including sudden death. Artificial intelligence (AI)-enabled electrocardiographic aging algorithms estimate biological age from 12-lead tracings and predict cardiovascular outcomes in the general population. However, their utility in genetic ACM/DCM has not been studied.
Methods: Retrospective review of 1,045 genotype-positive ACM/DCM patients was used to identify those with a pathogenic/likely pathogenic variant in ClinGen-classified definitive/strong evidence ACM/DCM-susceptibility genes. Following exclusion of patients without a baseline ECG for analysis (e.g. paced rhythms), the AI-ECG age gap (AI-EAG) was calculated by subtracting chronological from AI-ECG age. Genes were grouped into functional categories: desmosomal (PKP2, DSP, DSG2, DSC2, JUP), nuclear envelope (LMNA), sarcomeric (TTN, MYH7, TNNT2), cytoskeleton/Z-disc (FLNC, DES, DMD, BAG3), and regulatory/ion channel (PLN, RBM20, SCN5A). Cardiac MRI data included left ventricular structure, function, and late gadolinium enhancement (LGE) presence and pattern. Mann-Whitney U was used for group comparisons; results are shown as median (IQR).
Results: Overall, 824 patients (52.8% male; median age of 40.7 years, IQR 26.5–53.4; and median AI-EAG of 7.49 years, IQR 0.43–15.26) were included. DES variant-positive patients had the highest (19.98 years, IQR 9.66–23.21) and BAG3 variant-positive patients the lowest (–0.95 years, IQR -6.05–7.61) AI-EAGs. Among gene groups, nuclear envelope had the highest (15.12 years, IQR 6.79–25.17) and sarcomeric the lowest (5.75 years, IQR -0.69-14.01) AI-EAGs. Cardiac MRI was available for 538/824 (65%) of which 233/538 (43.3%) had LGE. No significant difference in AI-EAG was observed between LGE-positive and -negative patients (6.99 vs. 7.94 years; p=0.831). However, several LGE patterns were associated with significantly higher AI-EAGs: subepicardial (9.88 vs. 6.84; p=0.004), transmural (13.83 vs. 7.25; p=0.012), apical (12.89 vs. 7.17; p=0.002), and septal (8.91 vs. 7.19; p=0.016).
Conclusion: AI-EAG varies by gene and functional group, possibly reflecting gene-specific myocardial remodeling. While certain LGE patterns were linked to increased biological aging, overall LGE status was not. These findings suggest AI-EAG may capture disease activity that is distinct from LGE and could serve as a complementary, non-invasive biomarker in genetic ACM/DCM.
Sularz, Agata
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Ackerman, Michael
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Giudicessi, John
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Castrichini, Matteo
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Garmany, Ramin
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Bos, Johan
( Mayo Clinic College of Medicine
, Rochester
, Minnesota
, United States
)
Attia, Zachi
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Noseworthy, Peter
( MAYO CLINIC
, Rochester
, Minnesota
, United States
)
Friedman, Paul
( MAYO CLINIC
, Rochester
, Minnesota
, United States
)
Lopez-jimenez, Francisco
( MAYO CLINIC COLL MEDICINE
, Rochester
, Minnesota
, United States
)
Milone, Margherita
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Author Disclosures:
Agata Sularz:DO NOT have relevant financial relationships
| Michael Ackerman:DO have relevant financial relationships
;
Consultant:Abbott:Active (exists now)
; Royalties/Patent Beneficiary:UpToDate:Active (exists now)
; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now)
; Royalties/Patent Beneficiary:Solid Biosciences:Active (exists now)
; Royalties/Patent Beneficiary:Prolaio:Active (exists now)
; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now)
; Royalties/Patent Beneficiary:AliveCor:Active (exists now)
; Consultant:Tenaya Therapeutics:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:Invitae:Past (completed)
; Consultant:Illumina:Active (exists now)
; Consultant:Bristol Myers Squibb:Past (completed)
; Consultant:Boston Scientific:Active (exists now)
; Consultant:BioMarin Pharmaceutical:Past (completed)
| John Giudicessi:DO have relevant financial relationships
;
Consultant:Avidity Biosciences:Active (exists now)
; Consultant:Nuevocor Therapeutics:Active (exists now)
; Consultant:Citizen Health:Active (exists now)
| Matteo Castrichini:DO NOT have relevant financial relationships
| Ramin Garmany:DO NOT have relevant financial relationships
| Johan Bos:DO NOT have relevant financial relationships
| Zachi Attia:No Answer
| Peter Noseworthy:DO have relevant financial relationships
;
Royalties/Patent Beneficiary:Anumana:Active (exists now)
| Paul Friedman:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):Anumana:Active (exists now)
; Other (please indicate in the box next to the company name):Eko Health:Active (exists now)
; Other (please indicate in the box next to the company name):AliveCor:Active (exists now)
| Francisco Lopez-Jimenez:DO have relevant financial relationships
;
Advisor:Novo Nordisk:Active (exists now)
; Other (please indicate in the box next to the company name):Up-To-Date Author of chapter:Active (exists now)
; Consultant:Regeneron:Active (exists now)
; Advisor:WizeHealth:Past (completed)
; Royalties/Patent Beneficiary:Anumana:Active (exists now)
; Consultant:New Amsterdam Pharma:Past (completed)
; Consultant:MediWhale:Past (completed)
; Researcher:Select Research:Past (completed)
; Consultant:K-Health:Active (exists now)
; Consultant:Kento Health:Active (exists now)
; Advisor:Anumana:Active (exists now)
| Margherita Milone:DO NOT have relevant financial relationships